Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US business. The company launched 24 new products, with a pipeline of 100 products expected to offset slowing Revlimid sales. Analysts remain cautious, with valuations factoring in earnings upside.
Nifty may pause its rally near record highs. Analysts suggest dips are buying opportunities. Banking and metals sectors are highlighted. Support is seen at 25,400-25,500. A potential breakout from a Cup and Handle pattern is noted. Medium-term outlook remains positive for quality stocks. Sectors like BFSI, auto, and metal are expected to outperform.
